Abstract
Aims: Numerous non randomised studies published recently have suggested that the meropenem may be useful and safe antibacterial agents in neonatal severe infections caused by multi drag resistant (MDR) organisms. The aim of our report is to demonstrate the efficacy of meropenem in the treatment of severe infections in the newborns due to this organisms.
Methods: We reported the use of meropenem in 23 neonates, gestational age of 30. to 39. weeks and birth weight of 1250 - 3100 grams with severe infections due to MDR Escherichia coli, Klebsiellae pneumoniae and Serratia spp. Bacterial patogenes were isolated pretreatment in 14 of patients and all were susceptible to meropenem in vitro. Meropenem in dose of 20 mg/kg was administrated i.v. in 60 min infusion every 8-12 hours during 10-14 days as monotherapy as a second choice because of deterioration during conventional treatment.
Results: Clinical and bacterial response rate for meropenem were 100% for pneumonia, ITU and septicaemia, and 96% for NEC. One died. The incidence of drug related adverse events (mostly a slight decrease in number of thrombocytes) was 13.0%. No adverse events such as vomiting, diarrhea, glossitis, moniliasis, thrombocytosis, severe thrombocytopenia, eosinophylia, impairment of liver and renal function, rush, thrombophlebitis, Staphylococcus epidermidis colonisation and sezaures were observed.
Conclusion: These results demonstrate the efficacy of meropenem in the treatment of severe infections in newborns due to multiresistant gram-negative bacteria and can be used as appropriate empirical therapy and lead to improved outcome.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Avramovic, H., Bajcetic, M., Cakic, Z. et al. 1382 Use of Meropenem in Neonatal Severe Infections Caused by Multiresistant Gram Negative Bacteria. Pediatr Res 68 (Suppl 1), 684 (2010). https://doi.org/10.1203/00006450-201011001-01382
Issue Date:
DOI: https://doi.org/10.1203/00006450-201011001-01382